GlassScriptPhysician profile
Priya K Young
NPI 1992757751
$492,069.29
in general payments reported to CMS, 2019-2025
31 companies · $266K in 2025
The $266K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,959 · 2020: $695 · 2021: $2,923 · 2022: $16K · 2023: $36K · 2024: $165K · 2025: $266K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $380K · Travel and Lodging: $52K · Food and Beverage: $20K · Consulting Fee: $14K · Honoraria: $260 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $380,244.00 |
| Travel and Lodging | $52,049.13 |
| Food and Beverage | $20,033.45 |
| Consulting Fee | $13,563.00 |
| Honoraria | $260.08 |
| Education | $152.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $134,981.94 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $101,749.64 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $92,796.13 | 2019-2025 | |
| Galderma Laboratories, L.P. | $84,861.38 | 2019-2025 | Nemluvio, Aklief |
| Abbvie INC. | $64,088.48 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $4,202.36 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,801.66 | 2019-2025 | |
| Incyte Corporation | $1,125.52 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $904.91 | 2021-2025 | Bimzelx, Cimzia |
| Almirall LLC | $811.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $722.44 | 2019-2025 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $721.66 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $646.59 | 2019-2025 | Tremfya, Remicade, Simponi |
| Dermavant Sciences, INC. | $568.67 | 2022-2024 | Vtama |
| Leo Pharma INC. | $566.40 | 2021-2025 | Adbry, Anzupgo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $398.13 | 2019-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.82 | 2023-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $186.50 | 2024-2025 | Zoryve |
| Dermira, INC. | $157.09 | 2019 | |
| Stemline Therapeutics INC. | $112.48 | 2022 | |
| Celgene Corporation | $94.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $86.05 | 2019 | |
| Fresenius Kabi USA, LLC | $49.58 | 2024 | Idacio |
| Organon LLC | $47.54 | 2023-2025 | Vtama, Hadlima, Renflexis |
| Genentech USA, INC. | $32.97 | 2019 | |
| Lnhc, INC | $31.23 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.53 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $23.80 | 2023 | Dupixent |
| Aclaris Therapeutics, INC. | $14.38 | 2019 | |
| Mayne Pharma Commercial LLC | $11.96 | 2019 | |
| Prugen, INC. Pharmaceuticals | $4.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.